乳腺单纯小管癌患者的特征及长期生存情况

Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast.

作者信息

Poirier Éric, Desbiens Christine, Poirier Brigitte, Boudreau Dominique, Jacob Simon, Lemieux Julie, Doyle Catherine, Diorio Caroline, Hogue Jean-Charles, Provencher Louise

机构信息

Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec - Université Laval, Quebec City, QC, Canada.

Axe Oncologie, Centre de Recherche du CHU de Québec - Université Laval, Quebec City, QC, Canada.

出版信息

J Surg Oncol. 2018 May;117(6):1137-1143. doi: 10.1002/jso.24944. Epub 2017 Dec 4.

DOI:10.1002/jso.24944

PMID:29205352

Abstract

BACKGROUND AND OBJECTIVES

Pure tubular carcinomas (TC) of the breast are generally considered to have an excellent prognosis. This study aimed to analyze the characteristics and survival of patients with TC.

METHODS

This was a retrospective study conducted at the CHU de Québec-Université Laval. Databases were searched for all cases treated between April 1997 and December 2010. Survival was retrieved from the Province of Quebec Ministry of Health. Follow-up was censored on December 31, 2011. Overall survival (OS) was compared to patients with invasive ductal carcinoma (ICD) matched for age, tumor size, lymph node involvement, year of diagnosis, ER, PgR, and HER2, histological grade, lymphovascular invasion, and chemotherapy.

RESULTS

The frequency of TC was 2.9% (n = 223/7563). Tumors size was 7.4 ± 8.8 mm, without lymphovascular invasion (95.1%), ER-positive (98.2%), PgR-positive (69.5%), and HER2-negative (100%). Patients were followed up for 7.1 ± 2.7 years. The actuarial 13-year OS was 89.0% for TC, compared to 85.8% for IDC (P = 0.13). For TC, the 13-year OS was 95.8% in NO patients compared to 90.0% for N1-3 (P = 0.01).

CONCLUSION

Despite the general popular belief that patients with TC fare better than patients with IDC, the 13-year OS of TC was similar to that of grade I IDC.

摘要

背景与目的

乳腺纯管状癌（TC）通常被认为预后良好。本研究旨在分析TC患者的特征及生存情况。

方法

这是一项在魁北克大学拉瓦尔大学中心医院进行的回顾性研究。检索1997年4月至2010年12月期间治疗的所有病例数据库。从魁北克省卫生部获取生存数据。随访截止于2011年12月31日。将总生存（OS）与年龄、肿瘤大小、淋巴结受累情况、诊断年份、雌激素受体（ER）、孕激素受体（PgR）、人表皮生长因子受体2（HER2）、组织学分级、淋巴管浸润及化疗情况相匹配的浸润性导管癌（IDC）患者进行比较。

结果

TC的发生率为2.9%（n = 223/7563）。肿瘤大小为7.4±8.8毫米，无淋巴管浸润（95.1%），ER阳性（98.2%），PgR阳性（69.5%），HER2阴性（100%）。患者随访7.1±2.7年。TC患者13年精算OS为89.0%，而IDC为85.8%（P = 0.13）。对于TC，无淋巴结转移（NO）患者13年OS为95.8%，而有淋巴结转移（N1 - 3）患者为90.0%（P = 0.01）。